4DX — 4DMedical Income Statement
0.000.00%
Last trade - 00:00
- AU$230.62m
- AU$187.30m
- AU$0.72m
- 12
- 12
- 55
- 15
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.695 | 1.23 | 0.217 | 1.05 | 0.719 |
Cost of Revenue | |||||
Gross Profit | 0.064 | 0.111 | 0.125 | 0.281 | 0.684 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 6.89 | 15.2 | 19 | 25.5 | 32.2 |
Operating Profit | -6.19 | -14 | -18.7 | -24.5 | -31.5 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -6.49 | -22 | -21.4 | -24.5 | -31.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -6.49 | -22 | -21.4 | -24.6 | -31.5 |
Net Income Before Extraordinary Items | |||||
Net Income | -6.49 | -22 | -21.4 | -24.6 | -31.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -6.49 | -22 | -21.4 | -24.6 | -31.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.025 | -0.083 | -0.082 | -0.084 | -0.105 |
Dividends per Share |